Posted by Michael Wonder on 16 Aug 2021
FDA approves Lyumjev (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps
16 August 2021 - U.S. approval of pump use for Lilly's novel insulin is latest development designed to help people with diabetes manage blood sugar levels.
The U.S. FDA has approved an expanded label for Eli Lilly's rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) 100 units/mL indicated to improve glycemic control in adults with type 1 and type 2 diabetes, to include administration via continuous subcutaneous insulin infusion with an insulin pump.
